Creating a Soluble Binder to Endothelin-1 Based on the Natural Ligand Binding Domains of the Endothelin-1 (G-Protein-Coupled) Receptor

Abstract

Since its discovery in 1989, there has been extensive research on endothelin (ET)-1 physiology, as well as pathology. Accordingly, there is considerable research on the discovery of therapeutics based around ET-1, amongst which current treatment options include endothelin receptor antagonists. These target the ET-1 receptors, which are G-protein–coupled receptors (GPCRs). We have effectively developed a soluble form of a GPCR that binds to ligands, by constructing a fusion polypeptide of different endothelin receptor ligand binding domains. Phage experiments identified strong binders to ET-1. We then constructed Fc-fusions of the top binders and further binding assays revealed a KD of 21.2 nM for the Fc-ETtr1 construct and KD of 77.3 nM for the Fc-ETtr2 construct. These constructs are soluble and have the ability to bind and potentially sequester elevated ET-1 levels that are prevalent in different diseases. These results provide a novel approach to targeting GPCR–binding ligands, and thereby to contribute to a very important class of therapeutics.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Abbreviations

ECL:

Extracellular loop

ET-1:

Endothelin-1

ETA:

Endothelin A

ETB:

Endothelin B

ETtr:

Endothelin-1 traps

FFP:

Fc-fusion protein

GPCR:

G-protein-coupled receptor

HA:

Epitope human influenza hemagglutinin epitope

LBD:

Ligand binding domain

PBST:

Phosphate buffered saline tween

SB:

Super broth medium

STR:

Streptavidin

References

  1. Adachi M et al (1993) Functional domains of human endothelin receptor. J Cardiovasc Pharmacol 22(Suppl 8):S121–S124

    Article  CAS  PubMed  Google Scholar 

  2. Aurora R et al (1997) Local interactions in protein folding: lessons from the alpha-helix. J Biol Chem 272(3):1413–1416

    Article  CAS  PubMed  Google Scholar 

  3. Beck A, Reichert JM (2011) Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3(5):415–416

    Article  PubMed  PubMed Central  Google Scholar 

  4. Brazil M (2003) Setting a trap for cytokines. Nat Rev Drug Discov 2(2):90–90

    Article  CAS  Google Scholar 

  5. Chaumais MC et al (2015) Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. Am J Cardiovasc Drugs 15(1):13–26

    Article  CAS  PubMed  Google Scholar 

  6. Dinarello CA (2003) Setting the cytokine trap for autoimmunity. Nat Med 9(1):20–22

    Article  CAS  PubMed  Google Scholar 

  7. Fiore G et al (2005) Endothelin-1 triggers placental oxidative stress pathways: putative role in preeclampsia. J Clin Endocrinol Metab 90(7):4205–4210

    Article  CAS  PubMed  Google Scholar 

  8. Gabbay E, Fraser J, McNeil K (2007) Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 3(6):887–900

    CAS  PubMed  PubMed Central  Google Scholar 

  9. George EM, Granger JP (2011) Endothelin: key mediator of hypertension in preeclampsia. Am J Hypertens 24(9):964–969

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. George RA, Heringa J (2002) An analysis of protein domain linkers: their classification and role in protein folding. Protein Eng 15(11):871–879

    Article  CAS  PubMed  Google Scholar 

  11. Hiley CR et al (1992) BQ-123, cyclo(-D-Trp-D-Asp-Pro-D-Val-Leu), is a non-competitive antagonist of the actions of endothelin-1 in SK-N-MC human neuroblastoma cells. Biochem Biophys Res Commun 184(1):504–510

    Article  CAS  PubMed  Google Scholar 

  12. Huovinen T et al (2013) Two ScFv antibody libraries derived from identical VL-VH framework with different binding site designs display distinct binding profiles. Protein Eng Des Sel 26(10):683–693

    Article  CAS  PubMed  Google Scholar 

  13. Jain A (2013) Endothelin-1-induced endoplasmic reticulum stress in disease. J Pharmacol Exp Ther 346(2):163–172

    Article  CAS  PubMed  Google Scholar 

  14. Jain A et al (2012) Endothelin-1 induces endoplasmic reticulum stress by activating the PLC-IP(3) pathway: implications for placental pathophysiology in preeclampsia. Am J Pathol 180(6):2309–2320

    Article  CAS  PubMed  Google Scholar 

  15. Karet F, Davenport A (1994) Endothelin and the human kidney: a potential target for new drugs. Nephrol Dial Transplant 9(5):4

    Article  Google Scholar 

  16. Nelson J et al (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3(2):110–116

    Article  CAS  PubMed  Google Scholar 

  17. Orry AJ, Wallace BA (2000) Modeling and docking the endothelin G-protein-coupled receptor. Biophys J 79(6):3083–3094

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Patel S et al (2013) Selection of a high-affinity WW domain against the extracellular region of VEGF receptor isoform-2 from a combinatorial library using CIS display. Protein Eng Des Sel 26(4):307–315

    Article  CAS  PubMed  Google Scholar 

  19. Schneider MP, Boesen EI, Pollock DM (2007) Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 47:731–759

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Struck J, Morgenthaler NG, Bergmann A (2005) Proteolytic processing pattern of the endothelin-1 precursor in vivo. Peptides 26(12):2482–2486

    Article  CAS  PubMed  Google Scholar 

  21. Takasuka T et al (1992) Characterization of endothelin receptors ETA and ETB expressed in COS cells. J Biochem 112(3):396–400

    Article  CAS  PubMed  Google Scholar 

  22. Tam Tam KB et al (2011) Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance. Am J Obstet Gynecol 204(4):330e1–330e4

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank DM; Ms. Leela Jain for all her support. We also thank RC for funding this project.

Funding

This project was funded by private funding.

Author information

Affiliations

Authors

Contributions

AJ and VM participated in the research design. AJ, VM and HY conducted the experiments. AJ, KH, AJ and IJ contributed new reagents or analytic tools. VM and AJ performed the data analysis. AJ, VM, KH, AJ, MJ and IJ wrote or contributed to the writing of the manuscript.

Corresponding author

Correspondence to Arjun Jain.

Ethics declarations

Conflict of interest

The author(s) declare that they have no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jain, A., Mehrotra, V., Yong, H. et al. Creating a Soluble Binder to Endothelin-1 Based on the Natural Ligand Binding Domains of the Endothelin-1 (G-Protein-Coupled) Receptor. Int J Pept Res Ther 25, 107–114 (2019). https://doi.org/10.1007/s10989-017-9653-x

Download citation

Keywords

  • ECL
  • ETA receptor
  • ETB receptor
  • Endothelin-1 traps
  • FFP (Fc-fusion proteins)
  • GPCR (G-protein-coupled receptors)